<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954444</url>
  </required_header>
  <id_info>
    <org_study_id>OXY2018-01</org_study_id>
    <nct_id>NCT03954444</nct_id>
  </id_info>
  <brief_title>A Clinical Endpoint Bioequivalence Study of &quot;Oxymetazoline Hydrochloride Cream&quot;</brief_title>
  <official_title>A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product &quot;Oxymetazoline Hydrochloride Cream, 1%&quot; to Reference Product &quot;RHOFADETM Cream, 1%&quot; in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site&#xD;
      Therapeutic Equivalence Study with Clinical End-points Comparing Test Product &quot;Oxymetazoline&#xD;
      hydrochloride Cream, 1%&quot; to Reference Product &quot;RHOFADE™ Cream, 1%&quot; in the Treatment of&#xD;
      Moderate to Severe Persistent Facial Erythema of Rosacea&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 7, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician Erythema Assessment Score at Least 2 Grades Lower Than the Baseline (Day 1 Predose) Value</measure>
    <time_frame>29 days</time_frame>
    <description>The primary efficacy endpoint was the proportion of subjects with treatment success at all time points 3, 6, 9, and 12 hours post-application on Day 29. Treatment success was defined as having CEA score at least 2 grades lower than the baseline (Day 1 pre-dose) value. Clinician Erythema Assessment was measured as (0-clear, 1-almost clear, 2-mild, 3-moderate, 4- severe).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1105</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Oxymetazoline hydrochloride Cream, 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxymetazoline hydrochloride cream, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RHOFADE Cream, 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RHOFADE Cream, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymetazoline Hydrochloride</intervention_name>
    <description>Test Comparator</description>
    <arm_group_label>Oxymetazoline hydrochloride Cream, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rhofade Cream, 1%</intervention_name>
    <description>Reference Comparator</description>
    <arm_group_label>RHOFADE Cream, 1%</arm_group_label>
    <other_name>Oxymetazoline hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <other_name>Oxymetazoline hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Study subjects must have provided IRB approved written informed consent using the&#xD;
             latest version of the IRB informed consent form, (or assent in applicable&#xD;
             states/countries). In addition, study subjects must sign a HIPAA authorization, if&#xD;
             applicable.&#xD;
&#xD;
          -  (2) Healthy male or non-pregnant females, ≥18 years-of-age with a clinical diagnosis&#xD;
             of rosacea with persistent (non-transient) facial erythema.&#xD;
&#xD;
          -  (3) Ability to follow study instructions and complete subject diary without&#xD;
             assistance.&#xD;
&#xD;
          -  (4) Females of child bearing potential must not be pregnant or lactating at screening&#xD;
             visit and at baseline visit, as documented by a negative urine pregnancy test.&#xD;
&#xD;
          -  (5) Female subjects of childbearing potential must be willing to use an acceptable&#xD;
             form of birth control from the day of the first dose administration to 30 days after&#xD;
             the last administration of Investigational Product (IP). A sterile sexual partner is&#xD;
             NOT considered an adequate form of birth control.&#xD;
&#xD;
          -  (6) Moderate to severe persistent facial erythema associated with rosacea, defined as&#xD;
             a grade of ≥3 on the CEA scale as assessed by the Investigator at Screening and on&#xD;
             Baseline (Day 1) visit prior to study drug application.&#xD;
&#xD;
          -  (7) Moderate to severe persistent facial erythema associated with rosacea, defined as&#xD;
             a grade of ≥3 on the SSA scale as assessed by the subject at Screening and on Baseline&#xD;
             (Day 1) visit prior to study drug application.&#xD;
&#xD;
          -  (8) Stable erythema (for at least 3 months prior to screening) associated with&#xD;
             rosacea, with minimal variation from day to day and within each day, in the opinion of&#xD;
             the subject.&#xD;
&#xD;
          -  (9) Willingness to complete the required visits including short stay for at least 12&#xD;
             hours at the investigational site for 2 separate visits.&#xD;
&#xD;
          -  (10) Subjects who use make-up, facial moisturizers, creams, lotions, cleansers and/or&#xD;
             sunscreens must have used the same product brands/types for a minimum period of 4&#xD;
             weeks prior to Baseline, must agree not to change brand/type or frequency of use&#xD;
             throughout the study and must agree not to use make-up, facial moisturizers, creams,&#xD;
             lotions and/or sunscreens on the scheduled clinic visit day before the visit.&#xD;
&#xD;
          -  (11) Subject must be willing to avoid the use of abrasive cleansers or washes (e.g.,&#xD;
             exfoliating facial scrubs), adhesive cleansing strips (e.g., Bioré® Pore Strips) and&#xD;
             wax epilation on the face, during the entire duration of their study participation.&#xD;
&#xD;
          -  (12) Subject's willingness to minimize external factors that might trigger rosacea&#xD;
             flare-ups (e.g., spicy foods, thermally hot foods and drinks, hot environments,&#xD;
             prolonged sun exposure, strong winds, alcoholic beverages).&#xD;
&#xD;
          -  (13) Subject must be in good health and free from any systemic or dermatological&#xD;
             disorder (other than rosacea) that, in the opinion of the Investigator, will interfere&#xD;
             with the study evaluations or increase the risk of AEs.&#xD;
&#xD;
          -  (14) Any skin type or race, providing the skin pigmentation will allow discernment of&#xD;
             erythema.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Any of the following conditions: severe or unstable or uncontrolled cardiovascular&#xD;
             disease, clinically unstable hypertension, orthostatic hypotension, and uncontrolled&#xD;
             hypertension or hypotension, cerebral or coronary insufficiency, Raynaud's Syndrome,&#xD;
             thromboangiitis obliterans, scleroderma, Sjögren's syndrome, renal or hepatic&#xD;
             impairment.&#xD;
&#xD;
          -  (2) Subjects with narrow angle glaucoma.&#xD;
&#xD;
          -  (3) Females who are pregnant, breast feeding, or planning a pregnancy during the&#xD;
             study.&#xD;
&#xD;
          -  (4) Females of childbearing potential who do not agree to utilize an adequate form of&#xD;
             contraception during their participation in the study.&#xD;
&#xD;
          -  (5) Clinical signs of particular forms of rosacea (rosacea conglobata, rosacea&#xD;
             fulminans, isolated rhinophyma, isolated pustulosis of the chin) on the face or other&#xD;
             concomitant facial dermatoses that are similar to rosacea such as peri-oral&#xD;
             dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute&#xD;
             lupus erythematosus, or actinic telangiectasia that may interfere with the study&#xD;
             evaluations, in the opinion of the Investigator.&#xD;
&#xD;
          -  (6) Presence of ≥3 facial inflammatory lesions of rosacea at screening and baseline.&#xD;
&#xD;
          -  (7) Presence of any skin condition on the face that would interfere with the diagnosis&#xD;
             or assessment of rosacea, as determined by the Investigator.&#xD;
&#xD;
          -  (8) Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would&#xD;
             interfere with the study treatments or study assessments.&#xD;
&#xD;
          -  (9) History of drug or alcohol abuse within 12 months prior to the Screening visit.&#xD;
&#xD;
          -  (10 Known hypersensitivity or allergies to any component of the study treatment.&#xD;
&#xD;
          -  (11) Use within 12 hours prior to baseline of any topical products including, but not&#xD;
             limited to, lotions, creams, ointments, and cosmetics applied to the face (facial&#xD;
             cleanser is acceptable).&#xD;
&#xD;
          -  (12) Use 1 week prior to baseline of niacin ≥500 mg/day.&#xD;
&#xD;
          -  (13) Use within 2 weeks prior to baseline of products containing topical&#xD;
             corticosteroids, topical retinoids, topical antibiotics, topical anti-inflammatory,&#xD;
             topical treatment for rosacea, or topical treatment for acne.&#xD;
&#xD;
          -  (14) Use within 4 weeks prior to baseline of topical immunomodulators, systemic&#xD;
             antibiotics, systemic corticosteroids, systemic anti-inflammatory agents, systemic&#xD;
             treatment for rosacea, or systemic treatment for acne (other than oral retinoids,&#xD;
             which require a 6-month washout).&#xD;
&#xD;
          -  (15) Undergone 4 weeks prior to baseline any dermatologic or surgical procedure on the&#xD;
             face.&#xD;
&#xD;
          -  (16) Use within 3 months prior to baseline of any systemic immunomodulators known to&#xD;
             have an effect on rosacea.&#xD;
&#xD;
          -  (17) Use within 6 months prior to baseline of any oral retinoids (e.g., isotretinoin)&#xD;
             or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins&#xD;
             are allowed).&#xD;
&#xD;
          -  (18) Undergone 6 months prior to baseline any laser, light-source (e.g. intense pulsed&#xD;
             light, photodynamic therapy) or other energy-based therapy to the face.&#xD;
&#xD;
          -  (19) Exposed to excessive UV radiation within 1 week before Screening visit and/or&#xD;
             subject is unwilling to refrain from excessive exposure to UV radiation during the&#xD;
             course of the study.&#xD;
&#xD;
          -  (20) Current use of monoamine oxidase (MAO) inhibitors, barbiturates, opiates,&#xD;
             sedatives, systemic anesthetics, alpha-agonists, cardiac glycosides, beta blockers,&#xD;
             other antihypertensive agents, or oxymetazoline (e.g., eye drops, nasal sprays).&#xD;
&#xD;
          -  (21) Subject has participated in a clinical trial within 30 days or in a biologics&#xD;
             study within 6 months preceding admission of this study.&#xD;
&#xD;
          -  (22) Previous participation in this study.&#xD;
&#xD;
          -  (23) Inability to communicate well (i.e., language problem, poor mental development,&#xD;
             psychiatric illness or poor cerebral function), that may impair the ability to provide&#xD;
             written informed consent.&#xD;
&#xD;
          -  (24) Subject has any evidence of organ dysfunction, chronic infectious disease, system&#xD;
             disorder or has a condition or is in a situation that, in the Investigator's opinion,&#xD;
             that may put the subject at significant risk, may confound the study results, or may&#xD;
             significantly interferes with the subject's participation in the study.&#xD;
&#xD;
          -  (25) Employees or family members of the research center or Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>June 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03954444/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03954444/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxymetazoline Hydrochloride Cream, 1%</title>
          <description>Oxymetazoline hydrochloride cream, 1%&#xD;
Oxymetazoline Hydrochloride: Test Comparator&#xD;
Subjects applied once daily to face for 29 days</description>
        </group>
        <group group_id="P2">
          <title>RHOFADE Cream, 1%</title>
          <description>RHOFADE Cream, 1%&#xD;
Rhofade Cream, 1%: Reference Comparator&#xD;
Subjects applied once daily to face for 29 days</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Cream</title>
          <description>Vehicle cream&#xD;
Placebo: Placebo Comparator&#xD;
Subjects applied once daily to face for 29 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="379"/>
                <participants group_id="P2" count="382"/>
                <participants group_id="P3" count="344"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="366"/>
                <participants group_id="P2" count="366"/>
                <participants group_id="P3" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of prohibited therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with study drug application</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population also defined as in the Participant Flow</population>
      <group_list>
        <group group_id="B1">
          <title>Oxymetazoline Hydrochloride Cream, 1%</title>
          <description>Oxymetazoline hydrochloride cream, 1%&#xD;
Oxymetazoline Hydrochloride: Test Comparator</description>
        </group>
        <group group_id="B2">
          <title>RHOFADE Cream, 1%</title>
          <description>RHOFADE Cream, 1%&#xD;
Rhofade Cream, 1%: Reference Comparator</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Cream</title>
          <description>Vehicle cream&#xD;
Placebo: Placebo Comparator</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="379"/>
            <count group_id="B2" value="382"/>
            <count group_id="B3" value="344"/>
            <count group_id="B4" value="1105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="13.87"/>
                    <measurement group_id="B2" value="46.2" spread="14.01"/>
                    <measurement group_id="B3" value="47.2" spread="14.50"/>
                    <measurement group_id="B4" value="46.8" spread="14.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="258"/>
                    <measurement group_id="B4" value="824"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="182"/>
                    <measurement group_id="B4" value="589"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="516"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="337"/>
                    <measurement group_id="B4" value="1083"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Clinical Erythema Assessment Score</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0-Clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1-Almost Clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2-Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3-Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="292"/>
                    <measurement group_id="B3" value="273"/>
                    <measurement group_id="B4" value="852"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4-Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Subject Self-Assessment</title>
          <description>Assessment of the severity of Rosacea at baseline.&#xD;
Subjects were graded on a scale from 0 = no rosacea to 4 = very severe rosacea</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0-No Sign</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Almost Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="261"/>
                    <measurement group_id="B4" value="830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician Erythema Assessment Score at Least 2 Grades Lower Than the Baseline (Day 1 Predose) Value</title>
        <description>The primary efficacy endpoint was the proportion of subjects with treatment success at all time points 3, 6, 9, and 12 hours post-application on Day 29. Treatment success was defined as having CEA score at least 2 grades lower than the baseline (Day 1 pre-dose) value. Clinician Erythema Assessment was measured as (0-clear, 1-almost clear, 2-mild, 3-moderate, 4- severe).</description>
        <time_frame>29 days</time_frame>
        <population>Equivalence Analysis of the Primary Endpoint (Per Protocol Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Oxymetazoline Hydrochloride Cream, 1%</title>
            <description>Oxymetazoline hydrochloride cream, 1%&#xD;
Oxymetazoline Hydrochloride: Test Comparator</description>
          </group>
          <group group_id="O2">
            <title>RHOFADE Cream, 1%</title>
            <description>RHOFADE Cream, 1%&#xD;
Rhofade Cream, 1%: Reference Comparator</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Cream</title>
            <description>Vehicle cream&#xD;
Placebo: Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician Erythema Assessment Score at Least 2 Grades Lower Than the Baseline (Day 1 Predose) Value</title>
          <description>The primary efficacy endpoint was the proportion of subjects with treatment success at all time points 3, 6, 9, and 12 hours post-application on Day 29. Treatment success was defined as having CEA score at least 2 grades lower than the baseline (Day 1 pre-dose) value. Clinician Erythema Assessment was measured as (0-clear, 1-almost clear, 2-mild, 3-moderate, 4- severe).</description>
          <population>Equivalence Analysis of the Primary Endpoint (Per Protocol Population)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="286"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% Confidence Interval, should be within -20% to +20%</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1126</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 month adverse event data collection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxymetazoline Hydrochloride Cream, 1%</title>
          <description>Oxymetazoline hydrochloride cream, 1%&#xD;
Oxymetazoline Hydrochloride: Test Comparator</description>
        </group>
        <group group_id="E2">
          <title>RHOFADE Cream, 1%</title>
          <description>RHOFADE Cream, 1%&#xD;
Rhofade Cream, 1%: Reference Comparator</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Cream</title>
          <description>Vehicle cream&#xD;
Placebo: Placebo Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Androgen deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site acne</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site papules</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site paraesthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Application site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Application site pustules</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Eyelid infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals Development Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

